Latest Mitochondrial disease Stories
EPI-743 in phase 2B/3 development for Leigh syndrome MOUNTAIN VIEW, Calif., May 21, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the Japanese Ministry of Health,
Awarded by the Smaller Business Association of New England, Inc.
UAlberta researchers are taking a closer look at how two metabolic pathways interact to increase the lifespan of cells with mitochondrial defects.
Mitochondria, long known as "cellular power plants" for their generation of the key energy source adenosine triphosphate (ATP), are essential for proper cellular functions.
The conference offers physicians, nurses, and specialists an opportunity to understand more about identifying mitochondrial diseases, managing adults and children with mitochondrial disorders,
EPI-743 in two phase 2 development studies for Friedreich's ataxia MOUNTAIN VIEW, Calif., March 17, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the United States
First subject enrolled in pivotal clinical trial MOUNTAIN VIEW, Calif., March 10, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B/3 study entitled,
MitoAction and UMDF have joined together to congratulate Edison Pharmaceuticals in their announcement last week of a nearly $4.3 billion strategic partnership with Dainippon Sumitomo Pharma Co.,
EPI-743 in phase 2 development for Friedreich's ataxia MOUNTAIN VIEW, Calif., Feb.
Furthering the future of cell metabolism research in China BILLERICA, Mass., Jan.